These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 15228648)
1. [Application of ricin-immunotoxin mediated T cell depletion to allogeneic hematopoietic stem cell transplantation]. Lai YY; Guo NL; Huang XJ; Xu LP; Chen H; Wang SQ; Zheng HY; Li Y; Shen BF; Lu DP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):270-3. PubMed ID: 15228648 [TBL] [Abstract][Full Text] [Related]
2. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow. Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923 [TBL] [Abstract][Full Text] [Related]
3. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient]. Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503 [TBL] [Abstract][Full Text] [Related]
4. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Krance R; Heslop HE; Mahmoud H; Ribeiro R; Douglass E; Hurwitz C; Santana V; Kun L; Horowitz MM; Brenner MK Bone Marrow Transplant; 1993 Jan; 11(1):33-6. PubMed ID: 8431709 [TBL] [Abstract][Full Text] [Related]
5. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin. Michálek J; Collins RH; Vitetta ES Neoplasma; 2003; 50(4):296-9. PubMed ID: 12937844 [TBL] [Abstract][Full Text] [Related]
6. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center. Huang X; Liu D Clin Transpl; 2011; ():237-45. PubMed ID: 22755417 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Martin PJ; Pei J; Gooley T; Anasetti C; Appelbaum FR; Deeg J; Hansen JA; Nash RA; Petersdorf EW; Storb R; Ghetie V; Schindler J; Vitetta ES Biol Blood Marrow Transplant; 2004 Aug; 10(8):552-60. PubMed ID: 15282533 [TBL] [Abstract][Full Text] [Related]
8. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation. Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552 [TBL] [Abstract][Full Text] [Related]
9. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937 [TBL] [Abstract][Full Text] [Related]
10. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation. Nachbaur D; Eibl B; Kropshofer G; Meister B; Mitterschiffthaler A; Schennach H; Fischer G; Kopp M; Gunsilius E; Gastl G J Hematother Stem Cell Res; 2002 Aug; 11(4):731-7. PubMed ID: 12201962 [TBL] [Abstract][Full Text] [Related]
11. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704 [TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
13. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
14. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. Aversa F; Terenzi A; Tabilio A; Falzetti F; Carotti A; Ballanti S; Felicini R; Falcinelli F; Velardi A; Ruggeri L; Aloisi T; Saab JP; Santucci A; Perruccio K; Martelli MP; Mecucci C; Reisner Y; Martelli MF J Clin Oncol; 2005 May; 23(15):3447-54. PubMed ID: 15753458 [TBL] [Abstract][Full Text] [Related]
15. Severe acute graft-versus-host disease after T-cell depleted allogeneic stem cell graft from a second donor caused by persisting T-cells from the first donor. Wiesmann A; Bader P; Bamberg M; Faul C; Kanz L; Einsele H Bone Marrow Transplant; 2003 Sep; 32(5):511-3. PubMed ID: 12942098 [TBL] [Abstract][Full Text] [Related]
16. Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease. Laurent G; Maraninchi D; Gluckman E; Vernant JP; Derocq JM; Gaspard MH; Rio B; Michalet M; Reiffers J; Dreyfus F Bone Marrow Transplant; 1989 Jul; 4(4):367-71. PubMed ID: 2789084 [TBL] [Abstract][Full Text] [Related]
17. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547 [TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
19. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568 [TBL] [Abstract][Full Text] [Related]
20. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]